Globus Medical (Globus Medical) ROCE % : 2.16% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Globus Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Globus Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was 2.16%.

Globus Medical ROCE % Historical Data

The historical data trend for Globus Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Globus Medical ROCE % Chart

Globus Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

13.47

7.75

11.54

12.65

6.11

Globus Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															13.19	11.85	13.70	5.61	2.16

Globus Medical ROCE % Calculation

Globus Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	201.85	/	( ( (2076.126 - 159.204)	+	(5086.083 - 392.347) )	/ 2 )
	=	201.85	/	( (1916.922	+	4693.736)	/ 2 )
	=	201.85	/	3305.329
	=	6.11 %

Globus Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	103.816	/	( ( (5355.875 - 428.722)	+	(5086.083 - 392.347) )	/ 2 )
	=	103.816	/	( ( 4927.153	+	4693.736 )	/ 2 )
	=	103.816	/	4810.4445
	=	2.16 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Globus Medical (NYSE:GMED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Globus Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Globus Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Globus Medical (Globus Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Globus Medical Inc (NYSE:GMED) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GM0N:Germany

Address

2560 General Armistead Avenue, Audubon, PA, USA, 19403

Website

https://www.globusmedical.com

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Executives

Leslie V Norwalk	director	C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Dan Wolterman	director	3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130
John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Dan Lemaitre	director	2 MUSICK, IRVINE CA 92618
Keith W Pfeil	officer: SVP, Chief Financial Officer	GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Kelly Huller	officer: SVP, General Counsel	2560 GENERAL ARMISTEAD AVENUE, AUDOBON PA 19403
David D Davidar	director, officer: Vice President, Operations	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Daniel T Scavilla	officer: Senior VP and CFO	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David M Demski	director, officer: President and COO	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert Andrew Douglas	director	21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Stephen T Zarrilli	director	FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422
Anthony L Williams	officer: Senior VP of Bus. Devel. & GC	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Steven Payne	officer: Chief Accounting Officer	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David C Paul	director, 10 percent owner, officer: Chief Executive Officer	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403